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Abstract
Background: The aims of this study were to investigate predictive factors involved in effectiveness and safety of
enoxaparin for prevention of postoperative venous thromboembolism in aged Japanese total knee arthroplasty
(TKA) patients.
Methods: Japanese patients over 65 years old who were administered enoxaparin for TKA were enrolled in this
study. Their medical records were retrospectively reviewed. Data were corrected at the Izumi Regional Medical
Center, from September 2009 to March 2014. Patients were stratified into groups according to whether enoxaparin
was effective (no deep vein thrombosis event up to postoperative day 7) or not, and whether they had an adverse
drug event (ADE) or not.
Results: A total of 128 patients were included in this study. One hundred five (82.0%) patients were in the effective
group and 20 (15.6%) in the adverse drug event (ADE) group. Anemia (13 patients), abnormalities in liver function
tests (4 patients), clinically relevant non-major bleeding (4 patients) and urticaria (1 patient) were observed as ADEs.
Multivariate logistic regression analysis showed that the serum total protein level at postoperative day 1 (POD1,
before enoxaparin administration), was associated with effectiveness of enoxaparin, while the serum total protein
and hemoglobin level at POD1 were involved in ADE caused by enoxaparin.
Conclusions: Although further large scale studies will be warranted, our results suggest that serum total protein
level just before enoxaparin treatment for TKA relates to the effectiveness and safety of enoxaparin in a Japanese
aged population. In addition, the results indicate that the development of anemia should be carefully monitored
during enoxaparin treatment for TKA, particularly in patients with lower levels of serum hemoglobin before treatment.
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Background
Venous thromboembolism (VTE) is common after total
knee arthroplasty (TKA), and its incidence is particularly
high after orthopedic surgery. For example, the inci-
dence of deep vein thrombosis (DVT) and pulmonary
embolism after knee arthroplasty are 41–85% and 1.5–
10%, respectively, without anticoagulant therapy [1].
Enoxaparin sodium (enoxaparin), a low-molecular-
weight heparin, has been used to prevent VTE after
TKA, and has been shown to be effective in clinical tri-
als [2, 3]. Generally, enoxaparin has a predictable phar-
macokinetic profile and dose response curve, allowing
simplified dosing without the need for careful monitor-
ing through laboratory tests [4]. However, the standard
dose of enoxaparin is sometimes ineffective in DVT
high risk groups, such as intensive care patients [5]. In
addition, enoxaparin has been associated with severe
adverse drug events (ADE), such as bleeding, skin re-
action, liver failure, and anemia [6–8]. ncreasing age is
a common risk factor for ADE with many types of
medication [9–11], and enoxaparin is no exception.
Macie et al. suggested that increasing age was a risk
factor for bleeding during treatment with enoxaparin
[12]. Additionally, patient age was related to the effi-
cacy of enoxaparin in Phase III clinical trials (Trial
number: EFC10094, PK568, and PK567). However, it is
unclear which factors are associated with the effective-
ness and/or ADE of enoxaparin in aged patients.
Finding the predictive factors involved in the effective-
ness and/or ADE of anticoagulant therapy in aged pa-
tients is critical to avoid severe DVT and/or ADE. We
conducted this study to investigate the predictive factors
involved in the effectiveness and/or safety of enoxaparin
for TKA in aged Japanese patients.
Methods
Study design
We retrospectively analyzed the medical records of all
patients aged 65 years or older who were administered
enoxaparin for TKA. Data were corrected at the Izumi
Regional Medical Center, from September 2009 to
March 2014. No exclusion criteria were set.
The following data were collected: age, sex, height,
body weight, enoxaparin dose, previous history of DVT,
use of tourniquet, operative time, volume of bleeding
during surgery, laboratory values at postoperative day 1
(POD1) as the laboratory values before enoxaparin ad-
ministration, complications (hypertension, diabetes,
dyslipidemia, chronic heart failure, cerebral vascular
disease), concomitant medications that may interact
with enoxaparin (non-steroidal anti-inflammatory
drugs, low dose aspirin, clopidogrel, ticlopidine, cilosta-
zol, limaprost alfadex, warfarin, raloxifene).
To evaluate effectiveness, the patients were classified
into two groups, the “effective” group and “ineffective”
group. In this study, “effective” was defined as no DVT
event up to postoperative day 7. The safety of enoxa-
parin was evaluated according to presence (ADE (+)
group) or absence (ADE (−) group) of ADE. The la-
boratory values at POD7 were used for the assessment
of laboratory abnormalities. The ADE in this study
were defined as > grade 3 according to the National
Cancer Institute Common Terminology Criteria for
Adverse Events (version 4.0) [13] and/or clinically
relevant non-major (CRNM) bleeding [14]. This study
was approved by the Ethics Committee of Kumamoto
University (no. 915) and Izumi Regional Medical
Center (no. 20140908–1). All analyses were conducted
using anonymized data.
Statistical analysis
The statistical power of the association analyses of the
effectiveness and ADE of enoxaparin were calculated at
a significance (alpha) level of 0.05 (two-tailed) and an ef-
fect size (zeta) of 0.2–1.0 according to the sample size of
the present study using the G*Power software program
(version 3.1.9.2).
Continuous variables are expressed as mean ± stand-
ard deviation or median (range). The normality of data
were assessed using Shapiro-Wilk test. Univariate ana-
lyses to compare two groups were performed using
Welch’s t test, Mann–Whitney U test or Fisher's exact
test. Multivariate logistic regression analysis was used
to test the outcomes from univariate analysis. Parame-
ters that showed a correlation (P < 0.2) in the univariate
analysis were included in the multivariate analysis. Lo-
gistic regression was performed using stepwise model
selection according to Bayesian information criterion
[15]. A receiver operating characteristic (ROC) curve
for the significantly affecting factor of effectiveness and
safety of enoxaparin was plotted. Additionally, the cut-
off values were decided by Youden index. Significance
values were set at P < 0.05 for interpretation of the final
multivariate logistic regression model. The statistical
analyses were performed with JMP® Pro 12 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
Effectiveness of enoxaparin
A total of 128 patients were included in this study. One
hundred five (82.0%) patients were classified as the ef-
fective group. The characteristics of the effective and
ineffective groups are shown in Table 1. In univariate
analysis, serum total protein level at POD1, and the
number of patients who used a tourniquet were signifi-
cantly different between two groups. We evaluated the
incidence rate of ADE in the efficacy and ineffective
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groups, and no significant difference was observed be-
tween the groups (Additional file 1: Table S1).
The final model of multivariate logistic regression is
shown in Table 2. The serum total protein level at POD1
and body weight were identified as predictive factors of
effectiveness of enoxaparin (odds ratio: 0.22 and 1.06, re-
spectively). The ROC curve of serum protein level at
POD1 and body weight are shown in Fig. 1. The cut-off
value of serum protein level at POD1 and body weight
were 5.8 g/dL (specificity: 50.5%, sensitivity: 91.3%) and
52.0 kg (specificity: 70.5%, sensitivity: 56.5%), respect-
ively (Fig. 1).
Safety of enoxaparin
Twenty (15.6%) patients were classified as the ADE (+)
group. The characteristics of the ADE (+) and ADE (−)
groups are shown in Table 3. Of the patients in the ADE
(+) group, 13 had anemia, 4 had elevation of liver func-
tion tests, 4 had CRNM bleeding and 1 had urticaria
(see Additional file 2: Table S2). The serum total protein
level, lactate dehydrogenase level, and hemoglobin level
at POD1 were significantly lower in the ADE (+) group
than the ADE (−) group.
In multivariate logistic regression, the serum total pro-
tein level and hemoglobin level at POD1 were associated
with ADE caused by enoxaparin (Table 4). The ROC
curves of serum total protein level and hemoglobin level
at POD1 are shown in Fig 2. The cut-off value of serum
total protein level and hemoglobin level at POD1 were
5.6 g/dL (specificity: 71.3%, sensitivity: 75.0%) and 9.6 g/dL
(specificity: 91.7%, sensitivity: 55.0%), respectively.
Statistical powers
The statistical powers of the association analyses of the
effectiveness and ADE of enoxaparin with the factors
were 31.4 to 92.4% and 30.3 to 90.5%, respectively.
Discussion
In our study, we demonstrated that the predictive factor
for effectiveness of enoxaparin for TKA in aged Japanese
patients was serum protein level at POD1. We also
Table 1 Characteristics of patients classified according to
effectiveness of enoxaparin
Effective Ineffective P value
Case, no. (%) 105 (82.0) 23 (18.0) -
Age (years)a 77.2 ± 5.11 79.0 ± 4.51 0.10
Sex, no. (%)
male 25 (23.8) 3 (13.0) 0.40
female 80 (76.2) 20 (87.0)
Height (cm)b 150 (135–176) 145 (140–165) 0.08
Body weight (kg)b 57 (38–91) 51 (39–69) 0.11
Enoxaparin dose, no. (%)
2000 mg/day 36 (34.3) 9 (39.1) 0.64
4000 mg/day 69 (65.7) 14 (60.9)
Previous history of DVT, no. (%)
yes 4 (3.81) 3 (13.0) 0.11
Use of tourniquet, no. (%)
yes 35 (33.3) 15 (65.2) <0.01
Operative time, (min)b 110 (65–260) 100 (75–210) 0.14
Volume of bleeding
during surgery (mL)b
100 (0–1530) 70 (0–500) 0.33
Laboratory values at POD1
Total serum protein
(g/dL)a
5.85 ± 0.60 6.35 ± 0.53 <0.001
Serum creatinine
(mg/dL)b
0.68 (0.35–2.13) 0.64 (0.43–1.07) 0.15
BUN (mg/dL)b 13.5 (7.4–24.3) 12.0 (8.6–20.0) 0.16
AST (IU/L)b 20.0 (11.0–80.0) 20.0 (11.0–44.0) 0.68
ALT (IU/L)b 13.0 (5.0–50.0) 12.0 (6.0–57.0) 0.50
LDH (IU/L)b 199 (122–390) 216 (134–273) 0.20
ALP (IU/L)b 185 (94–398) 181 (122–337) 0.78
γ-GTP (IU/L)b 14 (7–460) 13 (8–143) 0.69
ChE (IU/L)b 220 (108–401) 231 (144–316) 0.90
Total bilirubin (mg/dL)b 0.8 (0.3–2.7) 0.9 (0.4–1.3) 0.74
WBC (103/μL)b 90 (45–405) 82 (62–158) 0.57
Hb (g/dL)a 10.9 ± 1.27 10.6 ± 1.21 0.28
Platelet (104/μL)a 18.2 ± 5.93 17.7 ± 4.61 0.62
CRP (mg/dL)b 4.57 (1.58–12) 5.52 (1.04–14.04) 0.41
Complications, no. (%)
Hypertension 72 (68.6) 19 (82.6) 0.21
Diabetes 13 (12.4) 2 (8.70) 1.00
Dyslipidemia 30 (28.6) 6 (26.1) 1.00
Chronic heart failure 6 (5.71) 0 (0.00) 0.59
Cerebral vascular
disease
6 (5.71) 0 (0.00) 0.59
Concomitant drugs, no. (%)
NSAIDs 100 (95.2) 21 (91.3) 0.61
Low dose aspirin 12 (11.4) 2 (8.70) 1.00
Clopidogrel 2 (1.90) 1 (4.35) 0.45
Table 1 Characteristics of patients classified according to
effectiveness of enoxaparin (Continued)
Ticlopidine 1 (0.95) 1 (4.35) 0.33
Cilostazol 1 (0.95) 1 (4.35) 0.33
Limaprost alfadex 5 (4.76) 3 (13.0) 0.15
Warfarin 6 (5.71) 1 (4.35) 1.00
Raloxifene 4 (3.81) 2 (8.70) 0.29
aData are expressed as mean ± SD, bData are expressed as median (range)
SE indicates standard error, POD1 post-operative day 1, BUN blood urea nitrogen,
AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate
dehydrogenase, ALP alkaline phosphatase, γ-GTP γ-glutamyl transferase, ChE
serum cholinesterase, WBC white blood cells, Hb hemoglobin, CRP C-reactive
protein, NSAIDs non-steroid anti-inflammatory drugs
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demonstrated that the serum total protein level and
hemoglobin level at POD1 were associated with ADE of
enoxaparin.
DVT is associated with morbidity and mortality in
hospitalized patients [16–18]. Hull et al. [19] reported
that rapidly achieving therapeutic levels of heparin can
improve prognosis of DVT. Therefore, the prediction of
enoxaparin effectiveness is clinically important to detect
DVT early. Our results indicated that the serum total
protein level at POD1 was lower in the effective group
than the ineffective group, and body weight was higher
in the effective group than the ineffective group. (Ta-
bles 1 and 2), and the cut-off value of serum total pro-
tein level at POD1 was 5.8 g/dL (Fig. 1). The AUC of
serum total protein level at POD1 was classified as hav-
ing moderate accuracy (0.7 < AUC ≤ 0.9) [20], while
the AUC of body weight was classified as having low
accuracy (0.5 < AUC ≤ 0.7). These findings suggest
that the serum total protein level prior to administra-
tion of enoxaparin is a useful predictive factor to im-
prove prognosis of DVT.
Our data demonstrated that the serum total protein
level at POD1 was lower in the ADE (+) than ADE (−)
groups (Tables 3 and 4), and the cut-off value was
5.6 g/dL (Fig. 2). These results show that the serum
total protein level prior to administration of enoxaparin
may also be associated with incidence of ADE caused
by enoxaparin.
In general, the pharmacokinetics and pharmaco-
dynamics of highly protein-bound drugs are affected by
plasma protein concentrations [21–23]. For example, hy-
poalbuminemia was associated with an increased risk of
over-anticoagulation by warfarin [24]. Enoxaparin is a
highly plasma protein-bound drug (Clexane® [inter-
view form]. KAKEN PHARMACEUTICAL CO.,LTD.,
Japan; Mar 2015, http://www.kaken.co.jp/medical/if/
clexane_201503if.pdf, Accessed Dec 20, 2016). Based
on this fact and our findings, it appears that the
pharmacology and ADE of enoxaparin might be en-
hanced by hypoproteinemia. Additionally, hypoalbu-
minemia is a major complication after surgery,
including TKA [25–27]. Kumar et al. [28] reported
that hypoproteinemia is a risk factor for DVT. These
findings suggest that hypoproteinemia is indirectly
associated with the efficacy of enoxaparin. Taken to-
gether, our results suggest that monitoring of total
serum protein level is critical to avoid DVT and ADE
in TKA patients.
In this study, the hemoglobin level at POD1 was also
associated with ADE caused by enoxaparin (Table 4).
Anemia was the most common ADE in our study and
hemoglobin level at POD1 was identified as s predictive
factor of ADE in our study. This finding is supported by
a previous study suggesting that drug-induced anemia is
common with enoxaparin treatment. [29]. In addition,
we observed that the hemoglobin value at POD7 was
significantly lower than POD1 in all 13 anemia pa-
tients (median: 8.9 g/dL vs. 7.5 g/dL; Additional file 3:
Figure S1). No significant relationship was observed
between bleeding and anemia in the patients as a
whole (Additional file 4: Table S3). Furthermore, the
volume of bleeding during surgery was not correlated
with the hemoglobin value at POD7 (Additional file 5:
Figure S2). Although the precise molecular mecha-
nisms are still unknown, our results suggest that enox-
aparin has the potential to decrease hemoglobin levels
and induce anemia. Enoxaparin may increase serum
Table 2 Multivariate logistic regression analysis of the factors
associated with effective of enoxaparin
Odds ratio (95% CI) P value
Serum total protein at POD1 0.22 (0.10–0.52) 0.0002
Body weight 1.06 (1.00–1.11) 0.0239
POD1 indicates post-operative day 1, CI confidence interval
Body weightSerum total protein level
Fig. 1 Receiver operating characteristic curve for predicting effectiveness of enoxaparin with serum total protein at POD 1. POD 1 indicates
post-operative day 1, AUC area under the curve
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alkaline phosphatase (ALP) and lactate dehydrogenase
(LDH) levels after orthopedic operation with high rate
(Clexane® [interview form]. KAKEN PHARMACEUT-
ICAL CO., LTD., Japan; Mar 2015, http://www.kaken.-
co.jp/medical/if/clexane_201503if.pdf, Accessed Dec 20,
2016). In this study, we also observed the increase in
serum ALP and LDH levels after (POD7) the treatment
of enoxaparin compared with before treatment (POD1)
(Additional file 6: Figure S3). Although the degrees of
the increase in these parameters did not meet the cri-
teria for ADEs in this study, serum ALP and LDH levels
should be carefully monitored.
This study has some limitations. First, we did not
evaluate the serum albumin level and non-bound enoxa-
parin concentration. Enoxaparin seems to mainly bind
to albumin. Albumin constitutes > 50% of serum total
protein and serum albumin level is generally relative to
serum total protein level. However, our data lacked in-
formation about serum albumin levels, so we could not
completely clarify a potential mechanism for serum total
protein affecting the effectiveness and safety of enoxa-
parin. As discussed above, hypoproteinemia seems to be
independently associated with the induction of DVT and
indirectly affects the efficacy of enoxaparin [28]. Further
studies will be needed to identify the pharmacokinetics
and pharmacodynamics of enoxaparin in patients with
and without hypoalbuminemia. Second, the population
in this study has gender bias because the prevalence of
osteoarthritis-related disability is higher among women
than men [30, 31]. In this study, we were not able to
Table 3 Characteristics of patients classified according to
presence or absence of severe adverse drug events after
enoxaparin administration
ADE (−) ADE (+) P value
Case, no. (%) 108 (84.4) 20 (15.6) -
Age (years)a 77.7 ± 5.00 76.5 ± 5.26 0.34
Sex, no. (%)
male 23 (21.3) 5 (25.0) 0.77
female 85 (78.7) 15 (75.0)
Height (cm)b 150 (138–175) 146 (135–176) 0.67
Body weight (kg)b 58 (38–85) 53.5 (39–91) 0.31
Enoxaparin dose, no. (%)
2000 mg/day 41 (38.0) 4 (20.0) 0.14
4000 mg/day 67 (62.0) 16 (80.0)
Previous history of DVT, no. (%)
yes 5 (4.63) 2 (10.0) 0.30
Use of tourniquet, no. (%)
yes 42 (38.9) 8 (40.0) 1.00
Operative time, (min)b 107 (65–260) 117.5 (85–230) 0.03
Volume of bleeding
during surgery (mL)b
90 (0–1530) 115 (0–420) 0.83
Laboratory values at POD1
Total serum protein
(g/dL)a
6.03 ± 0.59 5.46 ± 0.57 <0.01
Serum creatinine
(mg/dL)b
0.67 (0.35–2.13) 0.67 (0.46–1.08) 0.88
BUN (mg/dL)b 12.9 (7.4–23.3) 12.65 (9.2–24.3) 0.76
AST (IU/L)b 20.0 (11.0–52.0) 18.5 (11.0–80.0) 0.25
ALT (IU/L)b 13.0 (5.0–57.0) 12.0 (6.0–50.0) 0.39
LDH (IU/L)b 204.5 (131–390) 172 (122–250) <0.01
ALP (IU/L)b 185 (94–337) 188 (107–398) 0.86
γ-GTP (IU/L)b 14 (8–143) 11.5 (7–460) 0.23
ChE (IU/L)b 229 (128–392) 205 (108–401) 0.09
Total bilirubin (mg/dL)b 0.9 (0.3–2.7) 0.8 (0.4–2.0) 0.18
WBC (103/μL)b 85.5 (45–405) 94 (58–140) 0.35
Hb (g/dL)a 11.0 ± 1.17 9.75 ± 1.21 <0.01
Platelet (104/μL)a 18.3 ± 5.52 17.3 ± 6.75 0.56
CRP (mg/dL)b 4.56 (1.04–14.04) 5.425 (2.29–8.42) 0.20
Complications, no. (%)
Hypertension 79 (73.2) 12 (60.0) 0.28
Diabetes 14 (13.0) 1 (5.0) 0.46
Dyslipidemia 33 (30.6) 3 (15.0) 0.19
Chronic heart failure 4 (3.70) 2 (10.0) 0.24
Cerebral vascular
disease
5 (4.63) 1 (5.0) 1.00
Concomitant drugs, no. (%)
NSAIDs 102 (94.4) 19 (95.0) 1.00
Low dose aspirin 13 (12.0) 1 (5.0) 0.70
Table 3 Characteristics of patients classified according to
presence or absence of severe adverse drug events after
enoxaparin administration (Continued)
Clopidogrel 3 (2.78) 0 (0.0) 1.00
Ticlopidine 2 (1.85) 0 (0.0) 1.00
Cilostazol 2 (1.85) 0 (0.0) 1.00
Limaprost alfadex 7 (6.48) 1 (5.0) 1.00
Warfarin 7 (6.48) 0 (0.0) 0.60
Raloxifene 5 (4.63) 1 (5.0) 1.00
aData are expressed as mean ± SD, bData are expressed as median (range)
ADE (−) indicates absence of adverse drug events, ADE (+) presence of adverse
drug events, SE standard error, POD1 post-operative day 1, BUN blood urea
nitrogen, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH
lactate dehydrogenase, ALP alkaline phosphatase, γ-GTP γ-glutamyl transferase,
ChE serum cholinesterase, WBC white blood cells, Hb hemoglobin, CRP
C-reactive protein, NSAIDs non-steroid anti-inflammatory drugs
Table 4 Multivariate logistic regression analysis of the factors
associated with adverse drug events with enoxaparin
Odds ratio (95% CI) P value
Serum protein at POD1 0.27 (0.08–0.78) 0.0142
Hemoglobin 0.44 (0.24–0.75) 0.0022
POD 1 indicates post-operative day 1, CI confidence interval
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indicate clearly any gender differences due to the small
number of male patients compared with female patients.
Because most TKA patients are female and the validity
of our findings in male TKA patients is unclear, further
large scale studies will be needed to evaluate the gender
differences. Third, we did not conduct a VTE risk evalu-
ation in this study. Although the information about
DVT risk criteria (such as Wells score for DVT) is crit-
ical for evaluation of the efficacy of enoxaparin, we
lacked the parameters needed to calculate Wells score in
this study. Fourth, several factors (such as volume of
bleeding during surgery, ALT, γ-GTP, CRP, and con-
comitant drugs) were below the necessary limit of power
(i.e. 80%) to predict the effectiveness and/or ADE of
enoxaparin. Therefore, further investigations with a lar-
ger sample size are required before any definitive con-
clusions can be made. Finally, in this study, elevation of
liver function tests, such as AST, ALT and γ-GTP, was
observed as an ADE in 4 patients (Additional file 1:
Table S1). We also conducted a preliminary analysis of
the relationship between the abnormality in the liver
function tests and hemoglobin levels. However, signifi-
cant correlations were not observed among these param-
eters (Additional file 7: Figures S4 and Additional file 8
Figure S5). In the multivariate logistic regression ana-
lysis, we identified serum hemoglobin as a factor associ-
ated with ADE of enoxaparin in aged patients. However,
the abnormalities of serum liver parameters might not
be related to serum hemoglobin. Any possible link be-
tween lower blood hemoglobin at POD1 and the higher
incidence of total ADEs may be masked by the incidence
of anemia (identified by blood hemoglobin levels at
POD7). In this study we did not clearly evaluate the rela-
tionship between blood hemoglobin and other ADEs,
such as abnormality of liver function and bleeding be-
cause of the insufficient power of the analysis. Further
study to clarify the relationship between blood
hemoglobin and other ADEs will also be needed.
Conclusions
In this study, we have identified candidate factors, such
as serum total protein and hemoglobin levels, related to
the effectiveness and safety of enoxaparin treatment for
TKA in aged Japanese patients. The results suggest that
serum total protein level before treatment of enoxaparin
relates to the effectiveness and safety of enoxaparin in a
Japanese aged population. In addition, the results indi-
cate that patients should be carefully monitored for de-
velopment of anemia during enoxaparin treatment,
particularly those with lower levels of serum hemoglobin
before treatment. Further large scale studies are needed
to clarify the factors described.
Additional files
Additional file 1: Table S1. Comparison of the incidence rate of adverse
drug events (ADE) in the effective and ineffective groups. (DOC 70 kb)
Additional file 2: Table S2. Classification of the adverse drug events
reported in this study Adverse drug events. (DOC 71 kb)
Additional file 3: Figure S1. Hemoglobin levels at POD1 and POD7 in
anemia patients. In all 13 patients
in the anemia (+) group, the hemoglobin value at POD 7 was lower than
POD 1 with a significant difference (median: 8.9 g/dL vs 7.5 g/dL). The
bottom and top of the box show the 25 and 75% rankings and therefore
the interquartile range. The minimum and maximum rankings are
denoted by the lower and upper whiskers. Outliers are denoted by
circles. The two groups were compared using Wilcoxon signed-rank test.
(PPTX 65 kb)
Additional file 4: Table S3. Comparison of the incidence rate of
anemia in the bleeding (+) group and bleeding (-) group (DOC 70 kb)
Additional file 5: Figure S2. Correlation between volume of bleeding
during surgery and hemoglobin at post-operative day 7 (POD7). Significant
correlation was not observed between volume of bleeding during surgery
and hemoglobin at POD7. Statistical analysis were performed using Pearson
correlation coefficient. The red ellipse represents 95% confidence interval.
(PPTX 65 kb)
Additional file 6: Figure S3. Clinical laboratory data at post-operative
day (POD) 1 and POD7Alkaline phosphatase (ALP) and lactate dehydrogen-
ase (LDH) values at POD7 are significantly higher than POD1 (ALP (median):
185 IU/L vs 208 IU/L, LDH (median): 200 IU/L vs 214 IU/L, respectively). The
bottom and top of the box show the 25 and 75% rankings and therefore
Serum total protein level Hemoglobin level
Fig. 2 Receiver operating characteristic curve for predicting adverse drug events with enoxaparin with total protein level and hemoglobin level
at POD 1. POD 1 indicates post-operative day 1, AUC area under the curve
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the interquartile range. The minimum and maximum rankings are denoted
by the lower and upper whiskers. Outliers are denoted by circles. Two
groups were compared by Wilcoxon signed-rank. (PPTX 86 kb)
Additional file 7: Figure S4. Correlation between liver function test
value post-operative day (POD) 7 and hemoglobin at POD7. Significant
correlation was not observed between hemoglobin level at POD7 and
liver function tests POD7, such as aspartate aminotransferase, alanine
aminotransferase and gamma-glutamyl transferase. Statistical analysis
were performed using Pearson correlation coefficient. The red ellipse
represents 95% confidence interval. (PPT 182 kb)
Additional file 8: Figure S5. Correlation between liver function test
value at post-operative day (POD) 7 and hemoglobin at POD1. Significant
correlation was not observed between hemoglobin level POD1 and liver
function tests POD7, such as aspartate aminotransferase, alanine amino-
transferase and gamma-glutamyl transferase. Statistical analysis were
performed using Pearson correlation coefficient. The red ellipse repre-
sents 95% confidence interval. (PPT 185 kb)
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